Independent research tool — not a government agency. Official notices govern.Refreshed
GrantsJunctionAmerican funding, sourcedMethodology
OpenOpportunity RFA-CA-27-005

Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)

National Institutes of Health · Department of Health and Human Services

At a glance

Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required) is an open federal cooperative agreement opportunity from the National Institutes of Health (Department of Health and Human Services). Applications are due January 11, 2027. Individual awards are listed as up to $700K, with about 4 awards expected and $4.4M in total estimated funding. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 10 more. Cost sharing is not required. It is funded under Assistance Listing 93.394 (Cancer Detection and Diagnosis Research) and 1 other listing.

Summary assembled from the official notice's fields. The official notice governs.

Key facts

  1. Aug 31, 2026Posted
  2. Jan 11, 2027Application deadlinenext date
  3. Mar 5, 2027 (est.)Est. award date
  4. Mar 11, 2027Archived
Posted
Aug 31, 2026
Close date
Jan 11, 2027
Archive date
Mar 11, 2027
Est. award date
Mar 5, 2027
Award floor
Not specified
Award ceiling
$700,000
Est. total funding
$4,400,000
Expected awards
4
Cost sharing
Not required
Funding instrument
Cooperative Agreement
Opportunity category
Discretionary

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public colleges & universities
  • Federally recognized tribal governments
  • Public & Indian housing authorities
  • Native American tribal organizations
  • 501(c)(3) nonprofits
  • Nonprofits without 501(c)(3) status
  • Private colleges & universities
  • For-profit organizations (not small businesses)
  • Small businesses
  • Others (see notice)

Additional information on eligibility (from the notice)

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.

To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.

How to apply

0 of 8 done · progress saved in this browser

Assistance Listings

What is an ALN?

Reported obligations under ALN 93.394

Historical data · not a prediction
FY24$541M
FY25$602M
FY26$717M est.
Source: SAM.gov Assistance Listing 93.394. Program-wide totals, not awards from this specific opportunity.

Agency contact (as published)

National Institutes of Health
GTN-contacts@nih.gov
301-402-2541

Quick answers

When is the deadline for “Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)”?

According to the official notice, applications are due January 11, 2027. Confirm the deadline and submission time on Grants.gov before applying.

Who is eligible to apply for “Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)”?

The official notice lists these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 3 more. Additional restrictions may apply; review the full notice.

How much funding is available through “Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)”?

Per the notice, individual awards are listed as up to $700k, total estimated program funding is $4,400,000 and the agency expects to make about 4 awards.

How do I apply for “Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)”?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity RFA-CA-27-005), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.